Cargando…

A new staging strategy for chronic obstructive pulmonary disease

BACKGROUND: The best method for expressing lung function impairment is undecided. We tested in a population of patients with chronic obstructive pulmonary disease (COPD) whether forced expiratory volume in 1 second (FEV(1)) or FEV(1) divided by height squared (FEV(1)/ht(2)) was better than FEV(1) pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Martin R, Pedersen, Ole F, Dirksen, Asger
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699963/
https://www.ncbi.nlm.nih.gov/pubmed/18268941
_version_ 1782168558147469312
author Miller, Martin R
Pedersen, Ole F
Dirksen, Asger
author_facet Miller, Martin R
Pedersen, Ole F
Dirksen, Asger
author_sort Miller, Martin R
collection PubMed
description BACKGROUND: The best method for expressing lung function impairment is undecided. We tested in a population of patients with chronic obstructive pulmonary disease (COPD) whether forced expiratory volume in 1 second (FEV(1)) or FEV(1) divided by height squared (FEV(1)/ht(2)) was better than FEV(1) percent predicted (FEV(1)PP) for predicting survival. METHOD: FEV(1), FEV(1)PP, and FEV(1)/ht(2) recorded post bronchodilator were compared as predictors of survival in 1095 COPD patients followed for 15 years. A staging system for severity of COPD was defined from FEV(1)/ht(2) and compared with the Global Initiative for Obstructive Lung Disease (GOLD) staging system. RESULT: FEV(1)/ht(2) was a better univariate predictor of survival in COPD than FEV(1) and both were better than FEV(1)PP. The best multivariate model for predicting survival included FEV(1)/ht(2), age and sex. Comparing the GOLD stages with the FEV(1)/ht(2) groups found that survival was more coherent within each FEV(1)/ht group than it was within each GOLD stage. FEV(1)/ht(2) had 60% more people in its most severe group than the severest GOLD stage with these extra subjects having equivalently poor survival and had 155% more in the least severe group with equivalent survival. GOLD staging misclassified 51% of subjects with regard to survival. CONCLUSION: We conclude that GOLD criteria using FEV(1)PP do not optimally stage COPD with regard to survival. An alternative strategy using FEV(1)/ht(2) improves the staging of this disease. Studies which stratify COPD patients to determine the effect of interventions such as drug trials, rehabilitation, or management guidelines should consider alternatives to the GOLD classification.
format Text
id pubmed-2699963
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26999632009-06-23 A new staging strategy for chronic obstructive pulmonary disease Miller, Martin R Pedersen, Ole F Dirksen, Asger Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: The best method for expressing lung function impairment is undecided. We tested in a population of patients with chronic obstructive pulmonary disease (COPD) whether forced expiratory volume in 1 second (FEV(1)) or FEV(1) divided by height squared (FEV(1)/ht(2)) was better than FEV(1) percent predicted (FEV(1)PP) for predicting survival. METHOD: FEV(1), FEV(1)PP, and FEV(1)/ht(2) recorded post bronchodilator were compared as predictors of survival in 1095 COPD patients followed for 15 years. A staging system for severity of COPD was defined from FEV(1)/ht(2) and compared with the Global Initiative for Obstructive Lung Disease (GOLD) staging system. RESULT: FEV(1)/ht(2) was a better univariate predictor of survival in COPD than FEV(1) and both were better than FEV(1)PP. The best multivariate model for predicting survival included FEV(1)/ht(2), age and sex. Comparing the GOLD stages with the FEV(1)/ht(2) groups found that survival was more coherent within each FEV(1)/ht group than it was within each GOLD stage. FEV(1)/ht(2) had 60% more people in its most severe group than the severest GOLD stage with these extra subjects having equivalently poor survival and had 155% more in the least severe group with equivalent survival. GOLD staging misclassified 51% of subjects with regard to survival. CONCLUSION: We conclude that GOLD criteria using FEV(1)PP do not optimally stage COPD with regard to survival. An alternative strategy using FEV(1)/ht(2) improves the staging of this disease. Studies which stratify COPD patients to determine the effect of interventions such as drug trials, rehabilitation, or management guidelines should consider alternatives to the GOLD classification. Dove Medical Press 2007-12 2007-12 /pmc/articles/PMC2699963/ /pubmed/18268941 Text en © 2007 Miller et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Miller, Martin R
Pedersen, Ole F
Dirksen, Asger
A new staging strategy for chronic obstructive pulmonary disease
title A new staging strategy for chronic obstructive pulmonary disease
title_full A new staging strategy for chronic obstructive pulmonary disease
title_fullStr A new staging strategy for chronic obstructive pulmonary disease
title_full_unstemmed A new staging strategy for chronic obstructive pulmonary disease
title_short A new staging strategy for chronic obstructive pulmonary disease
title_sort new staging strategy for chronic obstructive pulmonary disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699963/
https://www.ncbi.nlm.nih.gov/pubmed/18268941
work_keys_str_mv AT millermartinr anewstagingstrategyforchronicobstructivepulmonarydisease
AT pedersenolef anewstagingstrategyforchronicobstructivepulmonarydisease
AT dirksenasger anewstagingstrategyforchronicobstructivepulmonarydisease
AT millermartinr newstagingstrategyforchronicobstructivepulmonarydisease
AT pedersenolef newstagingstrategyforchronicobstructivepulmonarydisease
AT dirksenasger newstagingstrategyforchronicobstructivepulmonarydisease